Inventiva provided a 3Q24 update which holds no surprises, reporting a cash position of € 13.9m. Following the € 94m in gross proceeds from the tranched equity raise (up to € 348m) announced in October 2024 and € 10m milestone from China partner CTTQ, Inventiva has a cash runway until the end of 2Q25 – this can be further extended with subsequent tranches based on certain conditions being met. With the financing overhang lifted, the focus is on recruitment for the phase 3 (NATiV3) trial of lani...
Inventiva reports 2024 Third Quarter Financial Information¹ Cash and cash equivalents at €13.9 million, as of September 30, 2024.Revenues of €1.3 million for the first nine months of 2024.On July 18, 2024, Inventiva issued royalty certificates for an amount of €20.1 million.Considering the receipt of €94.1 million in gross proceeds from the closing of the first part of the first tranche of the equity raise announced on October 14, 20242 and the receipt of the $10 million milestone payment under the amended license and collaboration agreement with CTTQ on November 18, 2024, the Company estim...
Inventiva publie ses informations financières du 3ème trimestre 2024¹ Trésorerie et équivalents de trésorerie à 13,9 millions d’euros au 30 septembre 2023.Chiffre d’affaires de 1,3 millions d’euros sur les neuf premiers mois de 2024.Emission de certificats de redevance le 18 juillet 2024, pour un montant de 20,1 millions d'euros. En tenant compte de la réception de €94.1 million brut à la suite de la réalisation de la première partie de la première tranche de la levée de fonds annoncée le 14 octobre 20242, et le versement du paiement d’étape par CTTQ reçu le 18 novembre 2024, la Société est...
Combined General Meeting of December 11, 2024 - Availability of the preparatory documents Daix (France), Long Island City (New York, United States), November 20, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the availability of the preparatory documents for the Combined General Me...
Assemblée Générale Mixte du 11 décembre 2024 - Modalités de mise à disposition des documents préparatoires Daix (France), Long Island City (New York, Etats-Unis), le 20 novembre 2024 – Inventiva (Euronext Paris et Nasdaq : IVA), société́ biopharmaceutique spécialisée dans le développement clinique de petites molécules administrées par voie orale pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), également connue sous le nom de stéatohépatite non alcoolique (« NASH ») et d’autres maladies avec un besoin médical non satisfait significatif, annonce...
Statement of total voting rights and shares forming the company’s share capital as of November 4, 2024 Article R. 22-10-23 of the French Commercial Code Market : Euronext ParisISIN code / Mnemo : FR0013233012 / IVAWeb site : Date Number of Shares Outstanding Total voting rights,gross (1) Total voting rights,net (2) November 4, 2024 87 077 695 100 059 052 99 938 530 The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculate...
Information relative au nombre total de droits de vote et d’actions composant le capital social au 4 novembre 2024 Article R. 22-10-23 du Code de commerce Place de cotation : Euronext ParisCode ISIN / Mnémo : FR0013233012 / IVASite web : Date Nombre de titres composant le capital en circulation Nombre total de droitsde vote bruts(1) Nombre total de droits de vote nets(2) 4 novembre 2024 87 077 695 100 059 052 99 938 530 Le nombre de droits de vote bruts (ou droits de vote « théoriques ») sert de base de calcul pour les franchissements de seuil. Conformément à l’ar...
Onward announces a new grant from the EIC for € 6m over 5-years (of which Onward receives almost € 2m) to assess ARC-BCI in stroke patients. The grant underlines the platform potential of Onward's technologies. We continue to look out to FDA approval for Onward's first product ARC-EX, expected by YE24. We reiterate our € 9.1 TP and Buy rating.
ONWARD Medical Awarded Grant to Study Potential for ARC-BCI Therapy to Restore Movement after Stroke Grant supports the first clinical trials studying the potential for brain-computer interface (BCI) and artificial intelligence (AI) technology to restore thought-driven movement after stroke Funding also supports technology development of ARC-BCI System and ARC-IM Lead Approximately 15 million people worldwide experience a stroke each year EINDHOVEN, the Netherlands, Nov. 19, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company ...
Ageas reports on the progress of share buy-back programme Ageas reports on the progress of share buy-back programme Further to the initiation of the share buy-back programme announced on 28 August 2024, Ageas reports the purchase of 129,096 Ageas shares in the period from 11-11-2024 until 15-11-2024. DateNumber ofSharesTotal amount(EUR)Average price(EUR)Lowest price(EUR)Highest price(EUR)11-11-202421,0001,016,27948.3948.2448.5212-11-202434,1711,640,90848.0247.9048.4413-11-202442,1501,993,54647.3046.8647.6614-11-202426,1991,255,60047.9347.5448.1615-11-20245,576269,93748.4147.9648.66Total12...
Rapport d’Ageas sur le programme de rachat d’actions Rapport d’Ageas sur le programme de rachat d’actions Dans le cadre du programme de rachat d’actions annoncé le 28 août 2024, Ageas indique que 129.096 actions Ageas ont été achetées durant la période du 11-11-2024 au 15-11-2024. DateNombred’actionsMontant total(EUR)Cours moyen(EUR)Cours le plus bas (EUR)Cours le plus élevé (EUR)11-11-202421.0001.016.27948,3948,2448,5212-11-202434.1711.640.90848,0247,9048,4413-11-202442.1501.993.54647,3046,8647,6614-11-202426.1991.255.60047,9347,5448,1615-11-20245.576269.93748,4147,9648,66Total129.0966.17...
Ageas rapporteert over de inkoop van eigen aandelen Ageas rapporteert over de inkoop van eigen aandelen Naar aanleiding van het aandelen-inkoopprogramma dat op 28 augustus 2024 aangekondigd werd, maakt Ageas bekend dat er 129.096 eigen aandelen ingekocht werden tussen 11-11-2024 en 15-11-2024. DatumAantalaandelenTotaal Bedrag(EUR)Gemiddelde koers(EUR)Laagste koers(EUR)Hoogste koers(EUR)11-11-202421.0001.016.27948,3948,2448,5212-11-202434.1711.640.90848,0247,9048,4413-11-202442.1501.993.54647,3046,8647,6614-11-202426.1991.255.60047,9347,5448,1615-11-20245.576269.93748,4147,9648,66Totaal129....
Ageas and Amundi SA: Transparency notification Ageas and Amundi SA: Transparency notification In accordance with the rules on financial transparency*, Amundi SA has notified Ageas on 12 November 2024 that, on 8 November 2024, its interest has fallen below the statutory threshold of 3% of the shares issued by Ageas. Its current shareholding stands at 2.53%. Reason for the notificationAcquisition or disposal of voting securities or voting rights Downward crossing of the lowest threshold Notification byA parent undertaking or a controlling person Persons subject to the notification requir...
Ageas et Amundi SA: Notification de transparence Ageas et Amundi SA: Notification de transparence Conformément aux règles de transparence financière*, Amundi SA a introduit le 12 novembre 2024 une notification annonçant que, le 8 novembre 2024 sa participation a franchi, à la baisse, le seuil statutaire de 3% des actions émises par Ageas et atteint 2,53%. Motif de la notificationAcquisition ou cession de titres conférant le droit de vote ou de droits de voteFranchissement vers le bas du seuil minimumNotification parUne entreprise mère ou une personne détenant le contrôle Personne(s) tenu...
Ageas en Amundi SA: Transparantiekennisgeving Ageas en Amundi SA: Transparantiekennisgeving Amundi SA informeerde Ageas op 12 november 2024, overeenkomstig de financiële transparantievereisten*, dat zijn belang op 8 november 2024 onder de statutaire drempel van 3% van de door Ageas uitgegeven aandelen is gedaald en nu 2,53% bedraagt. Reden van de kennisgevingVerwerving of overdracht van stemrechtverlenende effecten of stemrechtenOnderschrijding van de laagste drempelKennisgeving doorEen moederonderneming of een controlerende persoon Kennisgevingsplichtige perso(o)n(en)Zie bijlage 1a. Da...
We maintain our Outperform rating on CaixaBank, one of our Top Picks in the sector, with a higher target of € 7.2 vs € 6.7 and ahead of the CMD on 19 November. We are lifting our net income estimates by 7% for 2025-2026, to 7% above the consensus. The strategic update is set to highlight the wisdom of the business model diversification (long-term savings) to address the current transition phase on rates. Despite a solid market performance, the profile does not look to be fully reflec...
Nous réitérons notre opinion Surperformance sur CaixaBank, l’un de nos top picks du secteur, avec un OC porté à 7.2 € vs 6.7 € et en amont du CMD du 19/11. Nous relevons nos anticipations de RN de 7% sur 2025/2026 qui ressortent 7% supérieures au consensus. L’update stratégique devrait mettre en avant la pertinence de la diversification du business model (épargne LT) face à la transition actuelle sur les taux. Malgré un solide parcours boursier, cela n’est pas pleinement reflété dans ...
>PSOE and Sumar spring a surprise in seeking to suddenly abolish the SOCIMI regime - On Monday 11 November, the PSOE reached a tax agreement with its Spanish government ally, “Sumar”, whereby the two parties want to abolish the SOCIMI REIT regime or at least part of its tax advantages. This sudden stance, which surprised Spanish property professionals, is thus different from the position that was presented just last week, namely to “encourage the construction of affor...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.